EPO and type 2 diabetes mellitus: In a substudy of the EMPA-HEART(Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes)CardioLink-6 randomized clinical trial, empagliflozin treatment over six monthsled to an increase in plasma erythropoietin levels, increased hematocrit andreduced ferritin levels in patients with type 2 diabetes and coronary disease[98].